加载中
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
常规交易时段
US$7.95
−US$0.65 · -7.56%
盘中时间采用ET。市场数据可能有所延迟。
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
日内区间
当前US$7.95
52周区间
当前US$7.95
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
32
偏贵
情绪
55
多空交织
风险
51
风险偏高
动量
92
强势上行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
日内区间
当前US$7.95
52周区间
当前US$7.95
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|
| 销货成本 | 57.8万 USD | 70.1万 USD | 55.6万 USD | 57.4万 USD |
| 毛利 | −57.8万 USD | −70.1万 USD | −55.6万 USD | −57.4万 USD |
| 研究与开发 | 1.38亿 USD | 6782.2万 USD | 4911.9万 USD | 2657万 USD |
| 销售、一般及管理费用 | 3073.4万 USD | 1442.3万 USD | 760.7万 USD | 410.1万 USD |
| 营业费用 | 1.69亿 USD | 8224.5万 USD | 5672.6万 USD | 3067.1万 USD |
| 利息收入 | 551.8万 USD | 450.4万 USD | 109.9万 USD | 42.9万 USD |
| 折旧和摊销 | 57.8万 USD | 70.1万 USD | 55.6万 USD | 57.4万 USD |
| 营业利润 | −1.69亿 USD | −8294.6万 USD | −5728.2万 USD | −3124.5万 USD |
| 净利润 | −1.61亿 USD | −7758万 USD | −5570.9万 USD | −3001.6万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$29.20
上涨空间 267.30%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI716.31万0.00%2.3万亿 USD0.03%US$380.85-0.19%
Vanguard Extended Market ETFVXF282.31万0.00%954亿 USD0.05%US$232.05-0.63%
iShares Russell 2000 ETFIWM275.03万0.00%787.4亿 USD0.19%US$276.42-0.53%
iShares Russell 2000 Growth ETFIWO90.03万0.01%139.17亿 USD0.24%US$350.96-0.78%
Schwab U.S. Small-Cap ETFSCHA78.34万0.00%217.13亿 USD0.03%US$32.515-0.44%
Vanguard Russell 2000 ETFVTWO77.46万0.00%180亿 USD0.06%US$111.63-0.57%
Fidelity Enhanced Small Cap ETFFESM53.07万0.01%64.1亿 USD0.28%US$45.055-0.41%
Vanguard Health Care ETFVHT40.79万0.00%220亿 USD0.09%US$316.31-1.36%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMVanguard Health Care ETFVHTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
